Alexis McWhorter
Family · London, KYNPI 1871288357
Payments from drug & device makers
Across 132 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$565
- Novo Nordisk$512
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$196
- Lilly USA, LLC$189
- Phathom Pharmaceuticals, Inc.$120
- Si-bone, Inc.$99
- plus $676 from 18 others
What the payments were for
- Food & beverage$2,357100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $565 |
| Novo Nordisk | 34 | $512 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $196 |
| Lilly USA, LLC | 12 | $189 |
| Phathom Pharmaceuticals, Inc. | 6 | $120 |
| Si-bone, Inc. | 1 | $99 |
| Madrigal Pharmaceuticals | 3 | $81 |
| Antares Pharma, Inc. | 2 | $58 |
| Gilead | 3 | $56 |
| Sanofi | 3 | $55 |
| Amgen | 3 | $52 |
| Ardelyx, Inc. | 3 | $50 |
| Halozyme Inc | 2 | $48 |
| Aimmune Therapeutics, Inc. | 3 | $43 |
| Astellas Pharma US Inc | 3 | $41 |
| Bayer | 2 | $32 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Valinor Pharma, LLC | 1 | $20 |
| Pfizer | 1 | $16 |
| GSK | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$2,357 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 113 | $127,740 |
| OzempicSemaglutide | 36 | $39,477 |
| JardianceEmpagliflozin | 38 | $32,119 |
| EliquisApixaban | 33 | $27,137 |
| LinzessLinaclotide | 20 | $19,652 |
| TrintellixVortioxetine Hydrobromide | 13 | $13,286 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $6,664 |
| Repatha SyringeEvolocumab | 12 | $6,619 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,703 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $2,989 |
| Nebivolol Hcl | 26 | $1,867 |
| Duloxetine Hcl | 87 | $1,419 |
| Levothyroxine Sodium | 141 | $1,262 |
| Levocetirizine Dihydrochloride | 89 | $1,094 |
| Gabapentin | 112 | $1,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $189 | $127,740113 claims |
| Novo NordiskOzempic | $512 | $39,47736 claims |
| PfizerEliquis | $16 | $27,13733 claims |
| AbbVieLinzess, Namzaric, Synthroid | $565 | $26,97045 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $23 | $13,28613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.
Other family in London
- Robin HouseLondon$12K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.